Open

Lung Map Sub-Study S1900G

This is a study to learn more about effective treatments for non-small cell lung cancer. We want to compare how well different combinations of drugs work in treating this type of lung cancer. The drugs we are studying in this trial are capmatinib, osimertinib, and ramucirumab.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

You will have lab draws and physical exams every 2 weeks while you're on treatment. You will be taking capmatinib and osimertinib pills by mouth every day. You will record each dose in a pill diary. You may or may not receive infusions of ramucirumab once every two weeks. You will continue to have scans to monitor your cancer every few months.

Total length of participation:
3 years

Looking for Specific Volunteers

Able to participate:

You have EGFR mutated Non-Small Cell Lung Cancer
You have MET amplified lung cancer
You have previously been treated with Osimertinib
You are willing to be randomized to possibly receiving ramucirumab infusions
You are willing to undergo lab draws, physical exams, and CT scans

Not eligible if:

Have Small Cell Lung Cancer
Have never been treated with Osimertinib
Still have severe side effects from previous treatments
You have poor heart function
You have another cancer you are being treated for

Contact the Team

Visit Location

Contact & Visit Location

Additional Study Information

Principal Investigator

Brendan McNulty
UNC Hospitals - Rex

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Lung)

IRB Number

23-1078

ClinicalTrials.gov

NCT05642572

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.